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Introduction: Non-small-cell lung cancer harboring an activated epidermal growth factor receptor mutation
exhibits a good response to epidermal growth factor receptor-tyrosine kinase inhibitors; however, clinicians often
experience treatment failure following the development of resistance to epidermal growth factor receptor-tyrosine
kinase inhibitor.
Case presentation: We here report a case of a 56-year-old Japanese woman with non-small-cell lung carcinoma
with a secondary T790M mutation associated with resistance to epidermal growth factor receptor-tyrosine kinase
inhibitor that maintained sensitivity of brain metastases to epidermal growth factor receptor-tyrosine kinase
inhibitor. An autopsy showed that the primary focus had a T790M mutation; however, no mutations of T790M were
found in the brain metastases.
Conclusion: This case demonstrates the detection of T790M was associated with the clinical responsiveness to
epidermal growth factor receptor-tyrosine kinase inhibitor.Introduction
Gefitinib and erlotinib are epidermal growth factor receptor-
tyrosine kinase inhibitors (EGFR-TKIs). A non-small-cell
lung cancer (NSCLC) with an EGFR mutation exhibits a
good response to EGFR-TKI [1,2].
Despite initially showing a good response, most patients
present with recurrence of the disease; this is due to the de-
velopment of resistance to EGFR-TKI. Several mechanisms
of acquiring resistance to EGFR-TKI have been reported.
The existence of a second mutation of T790M [3,4], amp-
lification of c-met [5,6] and overexpression of hepatocyte
growth factor (HGF) [7] are known mechanisms of devel-
oping resistance to EGFR-TKI.
No standard treatment for patients who exhibit disease
progression during EGFR-TKI therapy has been established.
Clinicians sometimes experience cases in which, although
EGFR-TKI is unable to maintain disease control of the pri-
mary focus, the drug is effective against brain metastases.* Correspondence: sayakaohara@gmail.com
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EGFR mutation treated with gefitinib that resulted in the
progression of the disease while maintaining EGFR-TKI’s
effectiveness against brain metastases. We analyzed the
status of the EGFR mutation in the primary site and brain
metastases using a high-sensitivity method, the peptide
nucleic acid-locked nucleic acid polymerase chain reaction
(PNA-LNA PCR) clamp method [8].
Case presentation
A 56-year-old Japanese woman with a previous history of
cigarette smoking was referred to our hospital in September
2010 for a cough. Computed tomography (CT) showed
pleural effusion in her right thoracic cavity with a tumor in
the right middle lobe (Figure 1a). Cytology of the pleural
fluid revealed adenocarcinoma with an EGFR mutation of
an exon 19 deletion without a T790M mutation. Clinical
stage IV (cT4N3M1a) adenocarcinoma was diagnosed.
The first-line treatment was gefitinib, an EGFR-TKI,
which resulted in a partial response for 3 months (Figure 1b).
However, after 5 months of gefitinib treatment, we observed
an increase in her right pleural effusion in March 2011.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Computed tomography scans. a) On the initial medical examination, right pleural effusion and a mass in the middle lung field were
observed. b) After 3 months of gefitinib treatment, an improvement in the right pleural effusion and a decrease in the size of the primary lesion
were observed. c) After 5 months of gefitinib treatment, progression of the size of the mass was observed. d) Infiltration and atelectasis of the
right lung were observed.
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cinoma with an EGFR exon 19 deletion and a second muta-
tion of T790M associated with EGFR-TKI resistance.
We introduced cytotoxic chemotherapy. After five cycles
of carboplatin-pemetrexed, a relapse in her right pleural
effusion was noted (Figure 1c). After pleurodesis, followed
by four cycles of gemcitabine, the patient complained of
disorientation in October 2011. Despite the primary lesion
being well controlled, brain magnetic resonance imaging
(MRI) with gadolinium-diethylene-triamine pentaacetic
acid showed miliary brain metastases (Figure 2a).
The patient received whole-brain radiotherapy (30Gy/
10 fractions) until the end of October 2011. The fourth-line
treatment was erlotinib, which was started at the end of
October 2011.
The erlotinib treatment was continued until February
2012. By that time, her complaints of disorientation had
resolved, and brain MRI showed disappearance of her brain
metastases (Figure 2b). However, a chest CT showed
disease progression of the primary lesion, and her right
lung was almost in a state of atelectasis (Figure 1d).
We terminated the erlotinib treatment and initiated
therapy with docetaxel.
In April 2012, she was hospitalized for inability to walk
and depressed level of consciousness, brain MRI showed
carcinomatous meningitis (Figure 2c). Although shecould hardly eat, a rechallenge of erlotinib treatment
was undertaken.
After rechallenge of erlotinib, although there was no
improvement in her ability to walk, her level of conscious-
ness improved a little, and she could eat more. Brain MRI
demonstrated an improvement in the carcinomatous
meningitis in May 2012, 1 month after the rechallenge
of erlotinib treatment (Figure 2d). An improvement in
clinical symptoms and radiological findings show that
erlotinib treatment was effective.
However, her general status worsened, and she died of
dyspnea in July 2012.
An autopsy was performed after the patient’s death.
The autopsy showed that her right lung was almost entirely
infiltrated by the tumor. Direct invasion of the tumor into
her thoracic wall, pericardium and diaphragm was seen.
There were multiple metastases in both lungs and her liver,
right adrenal gland, peritoneum, brain, spinal cord, menin-
geal and lymph nodes.
Although brain metastasis was found at autopsy, the gross
pathology of her brain showed few metastases. Many small,
yellow nodules were found on her brain surface; however,
they resulted from invasion of foam cells, indicating traces
of metastases treated by previous chemotherapy.
The EGFR mutation in the primary lesion and brain
metastases was reassessed using the PNA-LNA PCR clamp
Figure 2 Brain magnetic resonance imaging (T1 gadolinium). a) Multiple, enhanced miliary nodules were observed. b) Following
whole-brain radiotherapy and erlotinib treatment, the complete disappearance of the metastatic lesions was observed. c) Following docetaxel,
an intensive signal in the cisterna of the posterior cranial fossa indicating carcinomatous meningitis was observed. d) After 1 month of the
rechallenge of erlotinib treatment.
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found in both the primary lesion and brain metastases.
Cytology showed the development of right pleural effusion
after gefitinib treatment, and a second mutation of T790M
was found in the primary lesion. However, the brain metas-
tases exhibited no mutations of T790M (Figure 3).
Discussion
Here we reported the autopsy case of a patient whose
brain metastases responded well to erlotinib, even after
acquiring resistance to EGFR-TKI at extracranial sites.
An analysis of the EGFR mutation using a PNA-LNA
PCR clamp method showed that no resistant mutations
(T790M) were detected in the sites of brain metastasis,
although this mutation was detected in the extracranial
sites. The detection of T790M was associated with the
clinical responsiveness to erlotinib in this case.Among the reported patients with NSCLC, approximately
20% to 40% develop brain metastases at some point
[9,10]. Several reports have suggested the possibility that
EGFR-mutated tumors are prone to brain dissemination
[11,12]. Omuro et al. reported that the central nervous
system (CNS) is a frequent site of disease recurrence in pa-
tients with NSCLC following an initial response to gefitinib,
regardless of disease control in the lungs [11]. Park et al.
reported that metastatic brain tumors in patients with
NSCLC harboring EGFR mutations respond well to EGFR-
TKIs as a first-line treatment and that the type of the
EGFR-TKI used has no effect on progression-free survival
or overall survival [13]. Controlling brain metastasis is
important in patients with NSCLC with EGFR mutations.
Jackman et al. reported a case of a patient with NSCLC
harboring EGFR mutation in which high-dose gefitinib was
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Figure 3 Chronology of the disease progression, treatment and epidermal growth factor receptor mutation status.
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[14]. In addition, the case indicates that extended gefitinib
exposure in the systemic lung cancer sites was associated
with the development of a systemic T790M resistance
mutation, whereas CNS metastases did not undergo this
secondary change.
Ruppert et al. reported a case of a lung adenocarcinoma
with a sensitive EGFR mutation in which the patient de-
veloped brain metastases with carcinomatous meningitis
and liver metastasis after he stopped taking EGFR-TKI [15].
Since a secondary T790M mutation was found on a liver
biopsy, but not in the CSF, the patient received erlotinib,
and the brain metastasis responded well to treatment.
As in that case report, our patient exhibited sensitivity
to erlotinib in brain metastases, even though the cancer
cells in the pleural effusion had acquired a resistant muta-
tion to EGFR-TKI, T790M. An autopsy analysis using the
PNA-LNA PCR clamp method showed that, although a
sensitive mutation to EGFR-TKI (exon 19 deletion) was
found in both the primary lesion and brain metastases, a
resistant EGFR mutation (T790M) was found only in the
primary site. In our case, as the disease progressed to the
patient’s CNS, applying cytotoxic chemotherapy became
difficult because of her worsened general status. In such a
case, although she died of progressive disease of T790M
mutated tumor cells in her thorax, EGFR-TKI, which was
effective in the brain metastases, was beneficial for her to
improve her quality of life.
These cases show that the possibility of persistent
cerebral TKI sensitivity should be considered in patientspresenting with CNS relapse after stopping an EGFR-TKI,
even those with a T790M-resistant mutation in non-
cerebral metastases. We examined the EGFR mutations
in the tumors in the lungs and brain only. The status of
the EGFR mutation was examined using the PNA-LNA
PCR clamp method; however, there are technical limita-
tions in the ability of this test to detect mutations. To help
us understand why T790M was not found in the brain me-
tastases, we tried to investigate the EGFR mutation status
in other metastatic sites such as the liver, adrenal gland and
spinal cord. However, because of the technical limitation of
fixation of formalin of an autopsy case, we could not extract
adequate deoxyribonucleic acid (DNA) to investigate their
EGFR mutation status.
Other types of resistance, such as met amplification
and/or HGF overexpression, have different effects on brain
metastases. Although these limitations exist, the differ-
ent distribution of the cancer cells that had acquired
the T790M mutation primarily explains the different
response to erlotinib observed between the intracranial
and extracranial sites in this case.
Conclusions
It is worth administering EGFR-TKI in patients with brain
metastases, even when the patient acquires EGFR-TKI
resistance. Based on the status of the EGFR mutation in
critical sites (particularly the CNS), clinicians should
decide whether to continue, stop or conduct a rechallenge
of EGFR-TKI when the disease progresses. Further in-
vestigations as to why resistance to EGFR-TKI appears
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order to provide better treatment to patients with NSCLC
with EGFR mutations.
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